Recognized in both pre-and post-approval pharmacovigilance operationsDURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a “Leader” for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea’s top position was recognized in both pre-and post-approval PV operations in Everest Group’s proprietary framework, which assess ...

Core Insights - Tech Mahindra has launched an autonomous pharmacovigilance solution utilizing NVIDIA AI software to improve drug safety management [1][3] - The solution aims to address industry challenges such as manual delays and data overload by enhancing the accuracy, speed, and efficiency of pharmacovigilance processes [1][3] Technology and Framework - The solution is powered by Tech Mahindra's TENO framework, which integrates NVIDIA's AI technology to automate and optimize pharmacovigilance workflows [2][4] - It incorporates NVIDIA AI Enterprise software, including NVIDIA NeMo™, NVIDIA NIM™ microservices, and NVIDIA AI Blueprints, to streamline various processes such as case intake and compliance management [2][4] Operational Benefits - The AI-driven solution can autonomously handle case classification, prioritization, and verification of pharmacovigilance emails, significantly reducing human error [2][3] - It processes over 1,000 daily cases of adverse drug reactions (ADR) and can reduce turnaround times by up to 40%, enhance data accuracy by 30%, and cut operational costs by 25% [3][4] Industry Impact - The collaboration between Tech Mahindra and NVIDIA aims to revolutionize drug safety management by transforming pharmacovigilance from a reactive to a predictive approach [3][4] - The integration of AI enhances the ability to monitor medicines throughout their lifecycle, supporting better identification of potential safety issues [4]